Lung Injury, Acute Clinical Trial
Official title:
Assessment of the Anti-Inflammatory Activity, Efficacy and Safety of Intravenous SB-681323 in Subjects at Risk for Development of Acute Lung Injury (ALI) or Acute Respiratory Distress Syndrome (ARDS).
This is an early phase (Phase IIa), randomized, double-blind, parallel group, multi-centre study for subjects with trauma (physical injury) who are at risk for developing Acute Lung Injury (ALI) or Acute Respiratory Distress Syndrome (ARDS). The primary purpose of the study is to evaluate the safety and tolerability of SB-681323, which is a potent, selective inhibitor of p38 alpha (MAPK) (prevents inflammation of tissue), in comparison to a placebo.
The acute respiratory distress syndrome (ARDS) is a form of severe lung injury (ALI)
characterized by hypoxemic respiratory failure (the lungs are unable to absorb oxygen to the
arterial blood) and non-cardiogenic pulmonary edema (accumulation of fluid in the lungs). The
syndrome may be caused by direct or indirect injury to the lungs. It is associated with a
mortality rate of up to 40-50%. There are no marketed pharmacologic therapies for this
devastating syndrome.
This study aims to assess the safety and tolerability of SB-681323, which is a potent,
selective inhibitor of p38 alpha mitogen-activated protein kinase.
The rationale behind the development of this drug is that there are elevated levels of
circulating pro-inflammatory agents, such as cytokines which are biological agents that
increase levels of inflammation in the lungs. These agents are part of an 'inflammatory loop'
and it may be beneficial to the condition to dampen this loop.
p38 mitogen activated protein kinase (MAPK) plays a major role in the regulation and
activation of intracellular proteins which are subsequently involved in the regulation of the
cytokines. The pathway is activated by 'stress', such as injury, causing the inflammation.
Therefore, 'dampening' this system should reduce the level of inflammation.
This study will investigate the anti-inflammatory activity, efficacy (effectiveness at
achieving the desired effect) and safety of SB-681323.
To measure the efficacy of the drug, biomarkers will be measured. Biomarkers are biological
agents in the body that are effected by the presence of specific injury or inflammation and
are directly or indirectly linked to a regulatory system of event in the body. They are used
to measure for the presence and severity of the condition in question. This study will
investigate biomarkers linked directly or indirectly to the p38 alpha regulatory
mechanism/system. We will be measuring biomarkers such as serum inflammatory biomarkers,
coagulation (blood clotting) system biomarkers, biomarkers of endothelial cell / neutrophil
interaction and biomarkers of lung epithelial cell injury.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00498251 -
Prevention of Lung Edema After Thoracic Surgery
|
N/A | |
| Completed |
NCT01597635 -
The Safety, Tolerability, PK and PD of GSK2586881 in Patients With Acute Lung Injury
|
Phase 2 | |
| Completed |
NCT00141726 -
Study of Enbrel (Etanercept) for the Treatment Sub-Acute Pulmonary Dysfunction After Allogeneic Stem Cell Transplant
|
Phase 2 | |
| Completed |
NCT03651817 -
Lung Protection Strategy in Open Heart Surgery: Which Tidal Volume is Better 8ml/kg or 6ml/kg
|
N/A | |
| Recruiting |
NCT05680831 -
Pulmonary and Inflammatory Responses Following Exposure to a Low Concentration of Ozone or Clean Air
|
Phase 1 | |
| Completed |
NCT03764319 -
Low Frequency, Ultra-low Tidal Volume Ventilation in Patients With ARDS and ECMO
|
N/A | |
| Completed |
NCT01640990 -
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of an Intravenous Infusion of GW328267X in Healthy Volunteers
|
Phase 1 | |
| Completed |
NCT01114009 -
Effects of Recruitment Maneuvers in Early Acute Lung Injury (ALI) and Acute Respiratory Distress Syndrome (ARDS) Patients
|
N/A | |
| Terminated |
NCT00715338 -
Effects of Oxygen on Lung Tissue During Anesthesia
|
N/A | |
| Recruiting |
NCT03202641 -
Open Lung Strategy, Gas Distribution and Right Heart Function in ARDS Patients
|
N/A | |
| Completed |
NCT03828630 -
Lung Ultrasound to Detect Pulmonary Complications in Critically Ill Parturients
|
||
| Completed |
NCT03905837 -
Impact of Lidocaine Administration on Postoperative Complications During Lung Resection Surgery
|
Phase 4 | |
| Completed |
NCT03023670 -
Lung Protection and Pediatric Cardiac Surgery
|
N/A | |
| Recruiting |
NCT05647967 -
Features of Regional Perfusion of Lung Consolidation
|
||
| Recruiting |
NCT04289324 -
Open Lung Maneuvers During High Frequency Oscillatory Ventilation in Preterm Infants
|
N/A | |
| Completed |
NCT05647382 -
Soluble VE-cadherin in Prediction and Diagnosis of Early Postoperative Hypoxemia After Cardiopulmonary Bypass
|
N/A | |
| Completed |
NCT05610475 -
Serum Level of Calpains Product as a Novel Biomarker of Acute Lung Injury Following Cardiopulmonary Bypass
|
N/A | |
| Recruiting |
NCT04511923 -
Nebulised Heparin to Reduce COVID-19 Induced Acute Lung Injury
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03637530 -
a Study Conducted About a New Mode of Ventilation in Laparoscopic Surgeries
|
N/A | |
| Completed |
NCT04344184 -
SAFEty Study of Early Infusion of Vitamin C for Treatment of Novel Coronavirus Acute Lung Injury (SAFE EVICT CORONA-ALI)
|
Phase 2 |